A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: procedure (650), etiquette (1), practice (609)

DVdSC (weekly cycles 9 onwards) DaratumumabSC-Bortezomib-Dexamethasone Ver1

Description
Chemotherapy Protocol Myeloma DVd SC (weekly) Bortezomib Daratumumab Dexamethasone Cycles 9 onwards Regimen • Myeloma – Bortezomib with daratumumab and dexamethasone Indication • Daratumumab
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVdSC-weekly-cycles-9-onwards-DaratumumabSC-Bortezomib-Dexamethasone-Ver1.pdf

Erlotinib

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) ERLOTINIB Regimen NSCLC - Erlotinib Indication Second line therapy of stage IIIB or IV
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Erlotinibver12.pdf

Prednisolone – Vincristine (Pre phase) Ver 1.1

Description
Chemotherapy Protocol LYMPHOMA PREDNISOLONE - VINCRISTINE (Pre phase) Regimen Lymphoma – Prednisolone-Vincristine (Pre phase) Indication Non-Hodgkin’s Lymphoma Toxicity Drug Prednisolone
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Prednisolone-–-Vincristine-Pre-phase-Ver-1.1.pdf

InP-MATRix

Description
Chemotherapy Protocol LYMPHOMA MATRix – CYTARABINE-METHOTREXATE-RITUXIMAB-THIOTEPA Inpatient Regimen Regimen • Lymphoma – InP-MATRix – Cytarabine-Methotrexate-Rituximab-Thiotepa Indication • Non-Hodgkin
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/InP-MATRix.pdf

MyelomaRCDCyclophosphamideDexamethasoneLenalidomidel(RCD)Ver1

Description
Chemotherapy Protocol MULTIPLE MYELOMA RCD-CYCLOPHOSPHAMIDE-DEXAMETHASONE-LENALIDOMIDE There are multiple versions of this protocol in use. Please ensure you have
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaRCDCyclophosphamideDexamethasoneLenalidomidelRCDVer1.pdf

MyelomaCTDa28CyclophosphamideDexamethasoneThalidomideAttenuated(CTDa)Ver1

Description
Chemotherapy Protocol MULTIPLE MYELOMA CTDa (28)-CYCLOPHOSPHAMIDE-DEXAMETHASONE-THALIDOMIDE (ATTENUATED) (CTDa-28) There are multiple versions of this protocol in use
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaCTDa28CyclophosphamideDexamethasoneThalidomideAttenuatedCTDaVer1.pdf

MyelomaCTD21CyclophosphamideDexamethasoneThalidomide(CTD)Ver1

Description
Chemotherapy Protocol MULTIPLE MYELOMA CTD (21)-CYCLOPHOSPHAMIDE-DEXAMETHASONE-THALIDOMIDE (21 days) There are multiple versions of this protocol in use. Please
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaCTD21CyclophosphamideDexamethasoneThalidomideCTDVer1.pdf

Nivolumab-Relatlimab

Description
Chemotherapy Protocol SKIN CANCER Nivolumab in combination with Relatlimab (Opdualag) Regimen • Skin – Nivolumab in in combination with Relatlimab (Opdualag) Indication The
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Nivolumab-Relatlimab-Ver1.pdf

Papers Trust Board - 10 September 2024

Description
Agenda Trust Board – Open Session Date 10/09/2024 Time 9:00 - 13:00 Location Conference Room, Heartbeat/Microsoft Teams Chair
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2024-Trust-documents/Papers-Trust-Board-10-September-2024.pdf

Cyclophosphamide-Epirubicin-Paclitaxel 21day

Description
Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-EPIRUBICIN-PACLITAXEL Regimen • Breast Cancer – Cyclophosphamide-Epirubicin-Paclitaxel Indication • Neoadjuvant / adjuvant therapy of early breast cancer
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Cyclophosphamide-Epirubicin-Paclitaxel-21day.pdf
191 to 200 of 698
Previous … 18 19 20 21 22 … Next